12/19
01:33 am
jazz
Is It Too Late To Consider Jazz Pharmaceuticals After Its Strong 2024 Share Price Rally? [Yahoo! Finance]
Low
Report
Is It Too Late To Consider Jazz Pharmaceuticals After Its Strong 2024 Share Price Rally? [Yahoo! Finance]
12/17
04:55 pm
jazz
Jazz Pharmaceuticals to Participate in Upcoming Investor Events [Yahoo! Finance]
Low
Report
Jazz Pharmaceuticals to Participate in Upcoming Investor Events [Yahoo! Finance]
12/17
04:15 pm
jazz
Jazz Pharmaceuticals to Participate in Upcoming Investor Events
Low
Report
Jazz Pharmaceuticals to Participate in Upcoming Investor Events
12/17
04:15 pm
jazz
Jazz Pharmaceuticals to Participate in Upcoming Investor Events
Low
Report
Jazz Pharmaceuticals to Participate in Upcoming Investor Events
12/12
04:58 am
jazz
3 Value Stocks We're Skeptical Of [Yahoo! Finance]
Low
Report
3 Value Stocks We're Skeptical Of [Yahoo! Finance]
12/10
07:21 am
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Low
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
12/6
07:51 am
jazz
Why Analysts Think Jazz Pharmaceuticals Story Is Changing After New Ziihera Growth Outlook [Yahoo! Finance]
Low
Report
Why Analysts Think Jazz Pharmaceuticals Story Is Changing After New Ziihera Growth Outlook [Yahoo! Finance]
12/5
09:18 am
jazz
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting [Yahoo! Finance]
Low
Report
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting [Yahoo! Finance]
12/5
09:00 am
jazz
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
Low
Report
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
12/3
04:31 pm
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
12/2
04:26 pm
jazz
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium [Yahoo! Fina
Low
Report
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium [Yahoo! Fina
12/2
04:05 pm
jazz
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
Low
Report
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
11/27
07:07 pm
jazz
A Look at Jazz Pharmaceuticals's Valuation After Breakthrough Phase 3 Ziihera Trial Results [Yahoo! Finance]
Low
Report
A Look at Jazz Pharmaceuticals's Valuation After Breakthrough Phase 3 Ziihera Trial Results [Yahoo! Finance]
11/27
02:49 pm
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
11/25
07:31 am
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) was downgraded by analysts at UBS Group AG from a "strong-buy" rating to a "hold" rating.
Low
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) was downgraded by analysts at UBS Group AG from a "strong-buy" rating to a "hold" rating.
11/24
07:19 am
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating.
Low
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating.
11/18
04:15 pm
jazz
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
Low
Report
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
11/18
04:15 pm
jazz
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
Low
Report
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
11/18
02:27 pm
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Wells Fargo & Company from $170.00 to $235.00. They now have an "overweight" rating on the stock.
Low
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Wells Fargo & Company from $170.00 to $235.00. They now have an "overweight" rating on the stock.
11/18
11:04 am
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Robert W. Baird from $160.00 to $209.00. They now have an "outperform" rating on the stock.
Medium
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Robert W. Baird from $160.00 to $209.00. They now have an "outperform" rating on the stock.
11/18
02:25 am
jazz
Jazz Pharmaceuticals: Stock Soars On Zanidatamab Data - I'm Still On The Fence [Seeking Alpha]
Medium
Report
Jazz Pharmaceuticals: Stock Soars On Zanidatamab Data - I'm Still On The Fence [Seeking Alpha]
11/18
02:25 am
jazz
Jazz Pharmaceuticals' And Zymeworks' Ziihera Success: A Pleasant Surprise [Seeking Alpha]
Medium
Report
Jazz Pharmaceuticals' And Zymeworks' Ziihera Success: A Pleasant Surprise [Seeking Alpha]
11/18
12:49 am
jazz
Jazz Pharma (JAZZ) Hits Fresh 52-Week High on Strong Cancer Treatment Trial [Yahoo! Finance]
Medium
Report
Jazz Pharma (JAZZ) Hits Fresh 52-Week High on Strong Cancer Treatment Trial [Yahoo! Finance]
11/17
02:09 pm
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) was given a new $194.00 price target on by analysts at Royal Bank Of Canada. They now have an "outperform" rating on the stock.
Low
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) was given a new $194.00 price target on by analysts at Royal Bank Of Canada. They now have an "outperform" rating on the stock.
11/17
12:37 pm
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Morgan Stanley from $185.00 to $205.00. They now have an "overweight" rating on the stock.
Low
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Morgan Stanley from $185.00 to $205.00. They now have an "overweight" rating on the stock.